Zusammenfassung
Mit zunehmender Entzifferung des menschlichen Genoms und erweiterten Kenntnissen genetischer
Informationen hat das Wissen um die genetischen Grundlagen krankheitsspezifischer
Phänotypen in der Forschung, Diagnostik und Therapie erheblich zugenommen. Ebenso
werden die bestehenden pharmakologischen Prinzipien durch neue Daten hinsichtlich
der genetischen Einflüsse auf die Haupt- und Nebeneffekte medikamentöser Therapien
ergänzt. Auch in der Behandlung neurologischer Krankheiten nimmt die Relevanz der
Pharmakogenetik bzw. -genomik auf Basis eines erweiterten Verständnisses der Pathomechanismen
von Krankheiten wie z. B. der Migräne und neurodegenerativer Erkrankungen (Morbus
Parkinson, amyotrophe Lateralsklerose, Morbus Alzheimer) stetig zu. Die folgende Übersicht
fasst das bestehende Wissen um die genetischen Grundlagen der pharmakologischen Therapieansätze
ausgewählter neurologischer Erkrankungen zusammen und versucht einen Ausblick auf
zukünftige Entwicklungen in diesem Gebiet zu geben.
Abstract
Increasing knowledge of the human genome regarding the genetic basis of diseases has
provided more specific information regarding research, diagnostics and drug-therapy.
Pharmacological principles with respect to genetic influences on drug effects and
adverse events have been supplemented by recent genetic data. This is true for the
treatment of neurological diseases, taking pharmacogenetics/pharmacogenomics into
account based on the extended knowledge of the pathomechanism of migraine, and neurodegenerative
diseases (Parkinson's disease, amyotrophic lateral sclerosis or Alzheimer's disease).
This review summarizes current knowledge on selected neurologic diseases and discusses
an outlook to future perspectives of this field.
Literatur
- 1
Lazarou J, Pomeranz B H, Corey P N.
Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective
studies.
J Am Med Assoc.
1998;
279
1200-1205
- 2
Goettler M, Schneeweiss S, Hasford J.
Adverse drug reaction monitoring - cost and benefit considerations. Preventability
of adverse drug reactions leading to hospital admissions.
Pharmacoepidem Drug Safety.
1997;
6 (S3)
S79-S90
- 3
Evans W E, Relling M V.
Pharmacogenomics: translating functional genomics into rational therapeutics.
Science.
1999;
286
487-491
- 4
Martin E R, Scott W K, Nance M A. et al .
Association of single-nucleotide polymorphisms of the tau gene with late-onset Parkinson
disease.
JAMA.
2001;
286
2245-2250
- 5
Gasser T.
Genetics of Parkinson's disease.
J Neurol.
2001;
248
833-840
- 6
Mouradian M M.
Recent advances in the genetics and pathogenesis of Parkinson's disease.
Neurology.
2002;
58
179-185
- 7
Scott W K, Nance M A, Watts R L. et al .
Complete genomic screen in Parkinson disease: evidence for multiple genes.
JAMA.
2001;
286
2239-2244
- 8
Tan E K, Khajavi M, Thronby J I. et al .
Variability and validity of polymorphism association studies in Parkinson's disease.
Neurology.
2000;
55
533-538
- 9
Swerdlow R H, Parks J K, Miller S W. et al .
Origin and functional consequences of the complex I defect in Parkinson's disease.
Ann Neurol.
1996;
40
663-671
- 10
Maimone D, Dominici R, Grimaldi L ME.
Pharmacogenomics of neurodegenerative diseases.
Eur J Pharm.
2001;
413
11-29
- 11
Williams T L, Day N C, Ince P G. et al .
Ca2+-permeable alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors: a
molecular determinant of selective vulnerability in amyotrophic lateral sclerosis.
Ann Neurol.
1997;
42
200-207
- 12
Takuma H, Kwak S, Yoshizawa T, Kanazawa I.
Reduction of Glu2R RNA editing, a molecular change that increases Ca2+ influx through AMPA receptors, selective in the spinal ventral grey of patients with
amyotrophic lateral sclerosis.
Ann Neurol.
1999;
46
806-815
- 13
Bensimon G, Lacomlez L, Meininger V. et al .
For the ALS/Riluzole study group. A controlled trial of riluzole in amyotrophic lateral
sclerosis.
New Engl J Med.
1994;
330
585-591
- 14
Selkoe D J.
Translating cell biology into therapeutic advances in Alzheimer's disease.
Nature.
1999;
399
A23-A31
- 15
Rosenberg R N.
The molecular and genetic basis of Alzheimer's disease: the end of the beginning.
Neurology.
2000;
54
2045-2054
- 16
Schenk D, Barbour R, Dunn W. et al .
Immunization with amyloid β attenuates Alzheimer-disease-like pathology in the Parkinson's
disease amyloid precursor protein mouse.
Nature.
1999;
400
173-177
- 17
Bard F, Cannon C, Barbour R. et al .
Peripherally administered antibodies against amyloid β-peptide enter the central nervous
system and reduce pathology in a mouse modell of Alzheimer disease.
Nat Med.
2000;
6
916-919
- 18
Saunders A M.
Gene identification in Alzheimer's disease.
Pharmacogenomics.
2001;
2
239-249
- 19
Saunders A M, Trowers M K, Shimkets R A. et al .
The role of apolipoprotein E in Alzheimer's disease: pharmacogenomic target selection.
Biochim Biophys Acta.
2000;
1502
85-94
- 20
Cacabelos R, Alvarez A, Fernandez-Novoa L, Lombardi V RM.
A pharmacogenomic approach to Alzheimer's disease.
Acta Neurol Scan.
2000;
S176
12-19
- 21
Poirier J, Delisle M C, Quirion R. et al .
Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment in Alzheimer's
disease.
Proc Natl Acad Sci USA.
1995;
92
12260-12264
- 22
Goadsby P J, Lipton R B, Ferrari M D.
Migraine - current understanding and treatment.
N Engl J Med.
2002;
346
257-270
- 23
Ophoff R A, Van den Maagdenberg A MJM, Roon K I. et al .
The impact of pharmacogenomics for migraine.
Eur J Pharm.
2001;
413
1-10
- 24
Cannon S C.
Voltage-gated ion channelopathies of the nervous system.
Clin Neurosci Res.
2001;
1
104-117
- 25
May A, Ophoff R A, Terwindt G M. et al .
Familial hemiplegic migraine locus on 19p13 is involved in the common forms of migraine
with and without aura.
Hum Genet.
1995;
96
604-608
- 26
Peroutka S J, Price S C, Wilhoit T L, Jones K W.
Comorbid migraine with aura, anxiety and depression is associated with dopamine D2
receptor (DRD2) Nco I allels.
Mol Med.
1998;
4
14-21
- 27
Glover V, Littlewood J, Sandler M. et al .
Biochemical predisposition to dietary migraine: the role of phenolsulfotransferase.
Headache.
1983;
23
53-58
- 28
Genomic Neurology.
Arch Neurol.
2001;
58
1739-1918
Dr. med. Claus G. Haase
Institut für klinische Pharmakologie · Pharma-Forschungszentrum · Bayer AG
42096 Wuppertal
Email: clausgert.haase.ch@bayer-ag.de
